Insulet (NASDAQ:PODD) Price Target Cut to $225.00 by Analysts at Stifel Nicolaus

Insulet (NASDAQ:PODD) had its target price decreased by Stifel Nicolaus from $250.00 to $225.00 in a report issued on Friday morning, Marketbeat.com reports. Stifel Nicolaus currently has a buy rating on the medical instruments supplier’s stock.

Several other brokerages also recently weighed in on PODD. Oppenheimer decreased their price target on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Benchmark reissued a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Citigroup upped their price objective on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research report on Wednesday. BTIG Research reduced their price objective on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research report on Tuesday, May 26th. Finally, Raymond James Financial set a $216.00 price objective on Insulet in a report on Monday, June 8th. Twenty-two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $237.08.

Insulet Stock Up 1.9%

PODD opened at $161.28 on Friday. The business has a 50 day moving average price of $152.93 and a two-hundred day moving average price of $211.33. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The company has a market cap of $11.17 billion, a PE ratio of 37.51, a P/E/G ratio of 1.10 and a beta of 1.11. Insulet has a 52 week low of $138.79 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% on a year-over-year basis. During the same period last year, the business posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts anticipate that Insulet will post 6.46 EPS for the current year.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently made changes to their positions in PODD. State Street Corp raised its stake in Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after purchasing an additional 65,317 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Insulet by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after buying an additional 41,019 shares in the last quarter. Invesco Ltd. raised its position in shares of Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after buying an additional 141,167 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares during the period. Finally, Norges Bank acquired a new stake in Insulet during the fourth quarter worth approximately $300,794,000.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Stifel kept a buy rating on PODD, although it lowered its price target from $250 to $225, suggesting the stock still has meaningful upside despite recent volatility. Benzinga reference
• Neutral Sentiment: Insulet also appeared in a positive-style growth note and an article discussing the stock’s valuation after a sharp decline, but these pieces did not provide fresh company-specific catalysts. Yahoo Finance reference
• Neutral Sentiment: Short-interest data showed no reported short interest as of July 10, so it does not currently signal a meaningful bearish positioning change.
• Negative Sentiment: Several law firms announced or promoted class-action lawsuits against Insulet over alleged securities fraud and Omnipod safety disclosures, which can create investor uncertainty and pressure the stock. PR Newswire reference

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.